Cadent Therapeutics Receives Milestone for the Initiation of Phase 1 Clinical Studies
Tags:
Phase 1
Company continues to advance pipeline of treatments for neurological conditions
CAMBRIDGE, Mass., Oct. 17, 2017 /PRNewswire/ -- Precision neuroscience company Cadent Therapeutics has earned a milestone payment from Novartis for the initiation of a Phase 1 clinical study of a subtype selective NMDA receptor negative allosteric modulator (NAM) for the treatment of treatment-resistant depression.
Cadent Therapeutics exclusively licensed the intellectual property for compounds that selectively modulate NR2B-containing NMDA receptors to Novartis. Novartis is conducting all research and development for the program.
"We are encouraged that Novartis has advanced our NR2B NAM molecule into clinical studies. This is an important milestone and one that will help support the advancement of Cadent's pipeline of first-in-class medicines to treat serious neurological diseases," said Michael Curtis, Ph.D., Chief Executive Officer, Cadent Therapeutics.
Cadent is discovering novel medicines designed to modulate dysregulated activity in the brain, tuning brain rhythms to restore motor and cognitive function. The company is advancing its pipeline of positive allosteric modulators for the treatment of spinocerebellar ataxia (SCA), essential tremor and cognitive impairment in patients with schizophrenia, with plans to enter the clinic in 2018.
About Cadent TherapeuticsCadent Therapeutics is a precision neuroscience company developing novel medicines that tune and modulate brain rhythms to restore cognitive and motor function in patients with serious neurological disease. The company leverages its unique precision neuroscience approach combining target specificity, patient selection, drug design and optimization, and novel quantitative endpoints to create first-in-class molecules to treat movement and cognitive disorders. Currently in early clinical development, Cadent is rapidly advancing its pipeline of therapies to treat spinocerebellar ataxia, essential tremor and schizophrenia. Investors include Atlas Venture, Clal Biotechnology Industries, Slater Technology Fund and Novartis. For more information, please visit cadenttx.com.
SOURCE Cadent Therapeutics
http://www.cadenttx.com
You just read:
News provided by
Oct 17, 2017, 07:00 ET
Share this article
Share this article
